Product image of Influsplit (Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic) supplied by GNH India

Influsplit

Active Ingredient:
Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic
Origin:
EU

Influsplit (Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic)

Influenza Virus B/Austria/1359417/2021‑Like Strain (B/Austria/1359417/2021, Bvr‑26) and Influenza A/Vic, the active ingredients in Influsplit, are influenza virus vaccines presented as an injectable solution for intramuscular use. It is intended to prevent influenza infection caused by influenza A and B viruses in individuals for whom vaccination is indicated.

GNH India supplies Influsplit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Glaxosmithkline Single Member A.E.B.E.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Influsplit is a seasonal influenza vaccine used to stimulate immunity against influenza A and B viruses.

  • Seasonal influenza: reduces the risk of infection and severe disease.
  • Influenza outbreaks: provides protection during community outbreaks.
  • High‑risk populations (e.g., elderly, chronic disease patients): lowers incidence of flu‑related complications.

How It Works

  • Influsplit contains split virus antigens from influenza A (Vic) and influenza B (Austria) strains. After intramuscular injection, the antigens are taken up by antigen‑presenting cells, prompting the immune system to generate antibodies against the hemagglutinin and neuraminidase proteins of the included strains, thereby establishing active immunity against subsequent influenza A and B exposure.

Side Effects

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Redness or swelling: localized erythema or edema.
  • Fever: low‑grade temperature rise within 24‑48 hours.
  • Headache or muscle aches: transient systemic symptoms.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Guillain‑Barré syndrome: rare neurological disorder with muscle weakness.
  • High fever or seizures: uncommon but potentially serious systemic reactions.

Precautions & Warnings

Influsplit should be administered with consideration of the following precautions.

  • Screen for severe allergy: assess history of hypersensitivity to vaccine components.
  • Delay vaccination: postpone in individuals with moderate or severe acute illness.
  • Pregnancy considerations: safety not established; weigh benefits and risks before use.
  • Concurrent immunizations: avoid administering live vaccines within 4 weeks.
  • Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Influsplit may interact with other therapies; monitor as indicated.

Major Interactions (Avoid)

  • Immunoglobulin therapy: may reduce vaccine efficacy.
  • Blood products: may interfere with immune response.
  • Live viral vaccines: avoid co‑administration within 4 weeks.

Moderate Interactions (Monitor Closely)

  • Antipyretics: may mask post‑vaccination fever.
  • Immunosuppressive drugs: may diminish antibody response.
  • Antihistamines: may lessen local reaction but are not contraindicated.

Frequently Asked Questions

Influsplit is an injectable influenza vaccine designed to prevent infection caused by influenza A (Vic) and influenza B (Austria) virus strains. It is administered to individuals at risk of seasonal flu to reduce the likelihood of illness and related complications.

The vaccine contains split virus antigens that stimulate the immune system to produce antibodies against the hemagglutinin and neuraminidase proteins of the included influenza strains. This immune response provides active protection against future exposure to those viruses.

The specific dose and schedule of Influsplit are determined by the prescribing healthcare professional based on age, health status, and local immunization guidelines. The prescriber will decide the appropriate amount for each patient.

Safety data for Influsplit in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against any unknown risks before vaccinating pregnant or breastfeeding individuals.

To place an order, submit an enquiry on the Influsplit product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Influsplit contains specific A/Vic and B/Austria strains, matching the current WHO‑recommended composition for the season. Compared with trivalent or other quadrivalent vaccines, it offers comparable protection but may differ in antigenic makeup, which can influence regional efficacy and supply considerations.

Influsplit must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Maintain the cold chain during transport and keep the product in its original packaging until use.

Influsplit is given as a single intramuscular injection, typically into the deltoid muscle of the upper arm. Administration is performed by a qualified healthcare professional following standard aseptic techniques.

The most serious adverse events reported with Influsplit include anaphylactic reactions, Guillain‑Barré syndrome, and severe systemic reactions such as high fever or seizures. Immediate medical attention is required if any of these occur after vaccination.

Individuals with a known severe allergy to any component of the vaccine, or who have experienced a previous severe reaction to a similar influenza vaccine, should not receive Influsplit. Consultation with a healthcare provider is essential for anyone with contraindications.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT